A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes

The Discussion calls the paper’s case the third report with apoE Toyonaka and homozygous apoE2/2, not the fourth. The Introduction identifies two earlier cases with MN-like histology. (LLM, conf=0.88)

Checked by a reasoning model — may be wrong.

The Introduction and Discussion describe three reported cases with MN-like lesions, including the paper’s own case, rather than four. The Discussion says the patient was born in a different area from the other two patients; it does not establish that all cases came from west-central mainland Japan. Page numbers are unavailable in our copy. (LLM, conf=0.84)

Checked by a reasoning model — may be wrong.

The Case presentation and clinical-course sections report increasing proteinuria and later renal dysfunction in this paper’s own patient. Discussion Table 1 reports persistent proteinuria in one previous case and relapse in another, but does not document declining renal function in those previous cases. Pages are not specified in our copy. (LLM, conf=0.85)

The Case presentation reports elevated serum apoE in the authors’ patient (7.5 mg/dL; normal range 2.4–5.2 mg/dL). The Discussion identifies one earlier case as normolipidemic, but neither its text nor Table 1 reports serum apoE concentrations for the two earlier cases. The source therefore does not establish that apoE was high in all reported cases regardless of dyslipidemia (page numbers unavailable in our copy). (LLM, conf=0.86)

The Discussion (Table 1; page unavailable) describes one of the three cases as normolipidemic and marks hypertriglyceridemia in the other two. The Case presentation reports elevated triglycerides and total cholesterol in the paper’s own case, but the copy does not give a cholesterol result for the Hirashima case. Thus, it does not establish that both remaining cases had hypercholesterolemia. (LLM, conf=0.85)

The 'Analysis of ApoE mutations and the clinical course' section reports that this paper's patient gradually developed renal dysfunction despite lipid-lowering treatment. Table 1 in the Discussion lists two other patients treated with prednisolone and cyclosporin, but reports persistent proteinuria or relapse—not a gradual decline in kidney function for either. The claim is therefore supported for the lipid-lowering case, not for both cases. (LLM, conf=0.86)

Table 1 in the Discussion records hypertriglyceridemia, foam cells, and lipoprotein thrombi in both the Hirashima case and the present case. The Pathological findings describe thrombi without fingerprintlike layers in the present case, but the copy does not establish that the Hirashima case’s thrombi were non-lamellar. The Discussion also says foam-cell infiltration is generally characteristic of apoE2 homozygote glomerulopathy, while describing thrombus-like material as atypical rather than frequently observed. (LLM, conf=0.86)

The Discussion (page unavailable) says apoE2 homozygote glomerulopathy is generally characterized by foam-cell infiltration in the glomerulus. It does not identify those cells as macrophages or explain the infiltration through an atherosclerosis–glomerulosclerosis mechanism; the Pathological findings section says this case’s lesions differed from foam cells. (LLM, conf=0.88)

The ‘Analysis of ApoE mutations and the clinical course’ section identifies both heterozygous Toyonaka (Ser197Cys) and homozygous apoE2 (Arg158Cys) in the patient; the Discussion also notes this combination in three cases. The paper describes their co-occurrence but does not state or establish that the variants are in linkage disequilibrium. No page number is available in our copy. (LLM, conf=0.83)

The Introduction describes ApoE Toyonaka (Ser197Cys) as a novel variant associated with distinctive glomerular lesions, and the Discussion says this patient had no consanguinity. But the Discussion calls this the third reported case and does not establish four non-consanguineous carriers; the count of four is not supported by this source. (LLM, conf=0.88)

The Discussion (page unavailable) reports three cases with glomerular lesions and the combination of APOE Toyonaka and homozygous APOE2/2. The mutation analysis (page unavailable) identifies Ser197Cys and Arg158Cys in the reported patient. These observations do not establish that lesions occur only when the other allele is APOE2. (LLM, conf=0.87)